leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics makes progress with drug delivery system for Parkinson's skin patches

The patches are based on the neurological drug Rotigotine, which is approved for the treatment of Parkinson's disease and restless legs syndrome in Europe and the US

XPhyto Therapeutics Corp. -
Global and European sales of Rotigotine patches last year came in at around US$500 million and C$250 million respectively, XPhyto noted

XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) revealed Monday that its German subsidiary had now finalized its formula for its skin patch to help Parkinson's disease sufferers ahead of human pilot studies earmarked for the third quarter of this year.

Vektor Pharma TF GmbH is an expert in the design, testing and manufacture of thin-film drug delivery systems, particularly transdermal patches and oral strips.

READ: XPhyto Therapeutics inks exclusive agreement with Oettinger Brewery for cannabis-infused beverages

The patches are based on the neurological drug Rotigotine, which is approved for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States.

"XPhyto's Parkinson's drug patch is an excellent example of the company's generic drug delivery strategy whereby approved generic drugs can be delivered using Vektor's novel drug delivery platforms," Hugh Rogers, CEO of XPhyto said in a statement.

"For both our transdermal patches and oral dissolvable films, we see the generic drug delivery model as a major opportunity for scalable value creation through expedited clinical evaluation and product launch, particularly in Europe."

Global and European sales of Rotigotine patches last year came in at around US$500 million and C$250 million respectively, XPhyto noted.

"We are extremely pleased with the TDS development results thus far. It appears that our goal of optimizing the dosage form efficiency, to reduce the amount of drug required in each patch, and improving overall patch adhesion to the patient's skin has been achieved," said Professor Dr. Thomas Beckert, the founder and managing director of Vektor.

Vector is now assessing what is needed to increase manufacturing capacity of the patches with a final decision expected to be made within 30 days.

Clinical sample manufacturing and analytical work will then begin in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany.

Human pilot studies in Europe are scheduled for the third quarter this year with results expected in the fourth quarter, XPhyto said.

Shares nudged up 0.31% in Toronto to C$3.19 each.

Contact the author at [email protected]

Quick facts: XPhyto Therapeutics Corp.

Price: 2.48 CAD

CSE:XPHY
Market: CSE
Market Cap: $152.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto to take big steps forward in 2021 in diagnostics, drug formulations,...

XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on what the company is planning for a very busy 2021. Rogers laying out the plan for three areas of their business. Rogers telling Proactive they expect major steps forward...

1 hour, 11 minutes ago

2 min read